sh-Oligopeptide-4 for Hair Regrowth
Evidence Review created on 11/08/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Thymosin Beta-4, Thymosin β4, Tβ4, Recombinant Human Thymosin Beta-4, rhTβ4, CG-Thymosin β4, Timbetasin
Motivation
sh-Oligopeptide-4 is the cosmetic ingredient name for a laboratory-made copy of thymosin beta-4, a small protein the body uses to repair tissue and to grow new blood vessels. It is added to hair serums, shampoos and clinic scalp treatments sold for thinning hair. For adults who treat hair retention as part of a long-term plan for health and appearance, it is one of several protein-based options promoted as an alternative or add-on to established hair-loss medicines.
Interest began when laboratory work in rodents connected the natural protein to the cells at the root of the hair that restart growth. The ingredient was later built into a multi-ingredient injectable formula studied mainly at one clinic group in India. Because it is sold as a cosmetic in many markets, products reach consumers without the review applied to medicines.
This review examines how sh-Oligopeptide-4 is thought to act on hair, what human and animal studies have actually measured, the safety record of the underlying protein, how it is used in practice, and where the evidence is missing.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
Expert commentary and research articles that discuss sh-Oligopeptide-4, or the molecule it copies, thymosin β4, in relation to hair follicles.
-
Benefits & Risks of Peptide Therapeutics for Physical & Mental Health - Andrew Huberman
Solo episode with dedicated segments on thymosin beta-4 and its fragment TB-500 for tissue repair and longevity, covering sourcing, dosing and risks; hair growth is not its focus.
-
Multiple potential roles of thymosin β4 in the growth and development of hair follicles - Dai et al., 2021
Narrative review of how the body’s own and applied thymosin β4 act on follicle stem cells and hair cycling in mice and cashmere goats.
-
Thymosin beta4 increases hair growth by activation of hair follicle stem cells - Philp et al., 2004
The founding National Institutes of Health study showing faster hair growth in rats and mice given thymosin β4, with migration of follicle stem cells.
-
QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study - Kapoor et al., 2020
Discloses that the injectable QR678 Neo contains sh-Oligopeptide-4 as a thymosin β4 mimic and reports cell-toxicity and mouse data; written by the formulation’s developers.
Only four items are listed: no fifth eligible source discussing sh-Oligopeptide-4 or thymosin β4 for hair in substantial depth was found outside the excluded categories.
No item from Rhonda Patrick, Peter Attia, Chris Kresser, Life Extension Magazine or Lifespan.io is listed: web and on-site searches of their platforms returned no content discussing thymosin β4 or sh-Oligopeptide-4 in relation to hair.
Grokipedia
Covers the molecule that sh-Oligopeptide-4 copies: structure, actin binding, wound-healing trials and rodent hair-growth findings, and states that robust human hair trials are lacking.
Examine
No Examine article on sh-Oligopeptide-4 or thymosin β4 exists.
ConsumerLab
No ConsumerLab article on sh-Oligopeptide-4 or full-length thymosin β4 exists.
Systematic Reviews
Two systematic reviews cover hair-loss formulations that contain sh-Oligopeptide-4; none examines the ingredient on its own.
-
Peptides for Hair Growth and Treatment of Hair Loss and Alopecia: A Systematic Review - Joerg et al., 2026
Fourteen peptide hair trials; rates QR678 (thymosin β4) and QR678 Neo (sh-Oligopeptide-4) at grade C, below the grade B of other peptide formulations.
-
Effectiveness of minimally invasive injectable modalities in the management of androgenetic alopecia among adults-A systematic review - Kumar et al., 2024
Sixteen injectable-therapy studies including the QR678 trials; written by the QR678 developers’ own research team, a direct conflict of interest.
No systematic review or meta-analysis addresses the risks of sh-Oligopeptide-4 or thymosin β4, so the safety side of the trade-off is unrepresented.
Mechanism of Action
sh-Oligopeptide-4 is a recombinant copy of human thymosin β4, made in Escherichia coli bacteria from a synthetic gene (EU CosIng record). Thymosin β4 is a 43-amino-acid protein (Philp 2004) whose core job is to bind actin (the cell-skeleton protein that drives cell movement) (review: Dai 2021).
Proposed hair actions, all from rodent studies:
- Stem-cell migration: it moves stem cells from the bulge (the follicle’s stem-cell reservoir) to the follicle base and raises MMP-2 (matrix metalloproteinase-2, an enzyme that remodels tissue scaffolding) (Philp 2004).
- Blood supply: it raises VEGF (vascular endothelial growth factor, a signal for new blood vessels) and activates ERK, AKT and p38 (cell growth and survival signaling cascades) (Gao 2015).
- Growth-phase switch: it tracks with Wnt/β-catenin signaling (the main pathway moving follicles into anagen, the active growth phase) (Gao 2016).
Competing view: in human scalp follicles kept alive in the laboratory, thymosin β4 reduced hair shaft production (Meier 2012). At roughly 4,900 daltons (a unit of molecular mass) (Dai 2021), it far exceeds the 500-dalton limit for crossing intact skin (Bos 2000), so leave-on serums may not reach follicles; nor does it act on dihydrotestosterone (the hormone that drives pattern hair loss).
Pharmacology: it is not receptor-selective and occurs in most cells, notably platelets and white blood cells (review: Dai 2021); its intravenous half-life is 0.5–2.08 hours (Wang 2021). Meprin-α and prolyl oligopeptidase (protein-cutting enzymes) cut it into Ac-SDKP (an anti-inflammatory four-amino-acid fragment) (Kumar 2016); no CYP (cytochrome P450, liver drug-processing enzymes) breakdown is described.
Historical Context & Evolution
Thymosin β4 was first characterized in the early 1980s among peptides extracted from the thymus, but it turned out to be made in most cells, where it acts as an actin-binding protein rather than a thymus hormone. Its original intended medical uses were tissue repair: a company program tested it on venous leg ulcers (Guarnera 2007), in eye drops for severe dry eye (Sosne 2015) and intravenously in healthy volunteers ahead of planned heart-attack use (Ruff 2010).
Hair entered the picture in the early 2000s, when a National Institutes of Health wound-healing group showed that thymosin β4 speeds hair growth in rats and mice and moves follicle stem cells (Philp 2004). Later Chinese work in genetically modified mice and cashmere goats, summarized in a review (Dai 2021), supported a role in follicle cycling.
The cosmetics industry then registered recombinant thymosin β4 under the name sh-Oligopeptide-4 as a skin-conditioning ingredient (EU CosIng record). In 2018 a Mumbai clinic group added thymosin β4 to an injectable growth-factor mix, QR678 (Kapoor 2018), and its successor, QR678 Neo, uses sh-Oligopeptide-4 instead (Kapoor 2020).
What changed over time is the delivery more than the evidence: the rodent findings stand, but a test on human scalp follicles in laboratory culture found that thymosin β4 reduced hair shaft production (Meier 2012), and no independent group has yet tested the ingredient alone on human scalps, so the human question remains open rather than settled in either direction.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no trial has tested sh-Oligopeptide-4 alone on a hair or scalp outcome in more than one research group, and the multi-ingredient injection trials come from one clinic network.
Medium 🟩 🟩
Scalp Seborrheic Dermatitis Relief ⭕️ Not Central to Hair Regrowth
In a randomized trial, 71 people with scalp seborrheic dermatitis (a flaky, inflamed scalp condition) used placebo, 2% ketoconazole lotion, or 0.5 mg/mL recombinant human thymosin β4 gel (the same molecule as sh-Oligopeptide-4) every other day for 4 weeks (Yu 2021). Flaking scores fell more with the gel than with placebo or ketoconazole. This bears on scalp health, not on regrowth itself. It is a single trial from one group.
Magnitude: The fall in flaking score exceeded placebo at every follow-up through week 24 (P < 0.001, where P is the probability of a result this large by chance) (Yu 2021); the paper reports the between-group differences only in graphs and gives no outcome figure in its text.
Low 🟩
More Terminal Hairs with Multi-Ingredient Injections
QR678 Neo, a scalp injection, contains sh-Oligopeptide-4 plus five other active peptides (Kapoor 2020). In 112 men undergoing transplantation, it raised terminal (thick, pigmented) hair counts versus transplantation alone (Gold 2025). Indirect: tested only in combination; the ingredient alone sped hair growth only in rodents (Philp 2004).
Magnitude: Terminal hair count reached 181.02 with QR678 Neo versus 150.45 with transplantation alone (Gold 2025), from baselines of 137.73 and 137.62 (Gold 2025), with P < 0.001 between groups in a single-blind design (Gold 2025); the source reports no difference figure or 95% CI (confidence interval, the range likely to contain the true value).
Speculative 🟨
No benefit is Speculative: the only animal-only evidence, rodent hair-growth studies, concerns the same hair-growth outcome as the Low item and is cited there.
Benefit-Modifying Factors
- Genetic polymorphisms: No gene variant has been studied as a modifier of response. Thymosin β4 is encoded on the X chromosome (TMSB4X gene), but whether its natural variation alters response to applied peptide is unknown.
- Baseline biomarkers: No blood or scalp marker predicts response. Trials enrolled people by hair-loss stage and measured hair counts and shaft diameter, not laboratory values (Gold 2025).
- Sex: The randomized transplant trial enrolled only men (Gold 2025); women were included in mixed-sex studies (Kapoor 2018) and a 20-woman series (Shome 2022), but none reported results by sex.
- Type of hair loss: A mechanism that recruits follicle stem cells needs living follicles; scarring alopecias (hair loss in which follicles are destroyed) are not expected to respond, and no study enrolled them.
- Scalp condition: Inflammatory scalp disease may limit regrowth; thymosin β4 gel improved seborrheic dermatitis in one trial (Yu 2021), which could matter where flaking coexists with thinning.
- Age: The randomized transplant trial enrolled men aged 25–50 (Gold 2025), with no age-stratified results; older adults with long-standing follicle shrinkage may have fewer follicles able to respond, an inference not yet tested.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: the only controlled data on thymosin β4 applied to skin come from one wound trial, and no hair trial compared adverse events against a placebo group.
Medium 🟥 🟥
Local Skin Reactions (Itching, Redness)
A placebo-controlled European trial applied thymosin β4 gel at three escalating strengths to venous leg ulcers for 84 days (Guarnera 2007). In its posted results, itching and redness were somewhat more frequent with the peptide; overall adverse-event rates were similar (NCT00832091). Ulcerated skin absorbs more than an intact scalp.
Magnitude: Itching occurred in 4 of 55 people on thymosin β4 gel (0.01–0.1%) versus 1 of 17 on placebo (NCT00832091), redness in 3 of 55 versus 0 of 17 (NCT00832091), and any non-serious adverse event in 35 of 55 versus 11 of 17 (NCT00832091).
Low 🟥
Injection and Microneedling Discomfort
Delivering QR678 Neo by scalp injection or derma roller (a roller of fine needles) causes local pain and redness; both were more common with the derma roller than with injection (Shome 2021). Indirect: multi-ingredient product, and the effects stem mainly from the needles.
Magnitude: Gold 2025, citing an earlier pilot study rather than its own trial data, reports minor itching after injection in 15% of patients, no control group (Gold 2025); in a 50-person comparison, redness and pain were more frequent with derma-roller than with injection delivery, with no event rates reported and no untreated comparison group (Shome 2021).
Tumor Promotion ⚠️ Conflicted
Raising thymosin β4 in melanoma cells increased lung metastases (cancer spread) in mice (Cha 2003), and high blood levels tracked with shorter liver-cancer survival (Wang 2023). Yet low levels predicted worse outcomes in myeloma (a bone-marrow blood cancer) (Caers 2010). Human data concern natural levels. Net: an unresolved, indirect signal.
Magnitude: Not quantified in available studies. No study has measured cancer incidence in people using applied thymosin β4; the human figures describe the body’s own tumor or blood levels, not exposure to the ingredient.
Speculative 🟨
Mislabeled or Substituted Unregulated Products
Online “thymosin” products may contain only a seven-amino-acid fragment; a doping-control laboratory found that fragment in TB-500 (Esposito 2012). Basis: product analysis only, no human outcome data.
Risk-Modifying Factors
- Genetic polymorphisms: No variant is known to change the risk of thymosin β4 products; no pharmacogenetic data exist.
- Baseline biomarkers: No laboratory value is known to modify risk. Intravenous phase 1 trials monitored blood counts, chemistry and tumor markers without signals (Wang 2021).
- Sex: No sex difference in adverse events has been reported; pregnancy has not been studied, so use during pregnancy or breastfeeding carries unknown risk.
- Cancer history: Because thymosin β4 promoted metastasis and new blood vessels in mouse tumors (Cha 2003), people with active or recent cancer carry the main theoretical risk.
- Bleeding tendency or anticoagulant (blood-thinning drug) use: Raises the chance of bruising and bleeding with scalp injection or derma-roller delivery; this concerns the needle procedure, not the peptide.
- Broken or inflamed scalp skin: Wounds and dermatitis increase absorption of large peptides compared with intact skin (Bos 2000), and needle delivery adds infection risk.
- Age: Older adults have higher baseline cancer risk and thinner, more fragile skin; no age-specific safety data exist for thymosin β4 products.
Key Interactions & Contraindications
Documented interactions:
- Intralesional corticosteroids (steroid injections into patches of hair loss; triamcinolone acetonide): combined with QR678 Neo in a placebo-controlled alopecia areata (patchy autoimmune hair loss) trial (Shome 2022); a systematic review (Kumar 2024) reports marked improvement in the combination group, with no interaction problem described.
- Follicular unit extraction hair transplantation: QR678 Neo injected before and after surgery and used as graft storage medium in a randomized trial; outcomes were better than transplantation alone, with no harm signal reported (Gold 2025).
- Topical minoxidil and oral finasteride: given together with QR678 formulations as combination therapy in a comparative study published as a letter (Shome 2021); its text is not indexed, and no interaction has been reported for the pairing.
Theoretical interactions (inferred from mechanism, not studied in humans):
- Anticoagulants and antiplatelet drugs (drugs that slow blood clotting; warfarin, apixaban, clopidogrel): inferred from needle trauma during injection or derma-roller delivery; consequence is bruising or scalp bleeding. Topical serums avoid the issue.
- Over-the-counter pain relievers that impair clotting (aspirin, ibuprofen, naproxen): inferred from reduced platelet function; consequence is more bruising after scalp needling. Avoiding them for 24–48 hours before needling sessions limits this.
- Angiogenesis inhibitors (cancer drugs that block new blood-vessel growth; bevacizumab, ramucirumab): inferred from thymosin β4’s VEGF-raising action opposing these drugs; consequence is a theoretical loss of effect of either agent.
- Copper peptides and growth-factor serums (GHK-Cu, platelet-rich plasma, a concentrate of the person’s own platelets): inferred from shared pro-repair and blood-vessel signaling; consequence is additive effect or added irritation.
- Hair supplements (saw palmetto, pumpkin seed oil): inferred from complementary action on the androgen (male-hormone) pathway; consequence is a possible additive outcome, with no known pharmacokinetic interaction.
Populations who should avoid sh-Oligopeptide-4:
- Active or recent cancer: inferred from tumor growth and metastasis promotion in mice (Cha 2003); no human data.
- Pregnancy and breastfeeding: inferred from thymosin β4’s role in tissue development and the absence of any reproductive safety data; no human data.
- Bleeding disorders, for needle delivery only: inferred from needle trauma to the scalp; no human data specific to this product.
- Active scalp infection or open lesions, for needle delivery only: inferred from the infection risk of microneedling through broken skin; no human data specific to this product.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Patch test before scalp use: a 48-hour test application on a small area behind the ear screens for the itching and redness seen with thymosin β4 gel (NCT00832091).
- Intact-skin topical use over needles: topical serums avoid the pain, redness and infection risk of injection or derma rollers; where needling is used, injection caused less redness than rolling (Shome 2021).
- Sterile clinic technique for injections: single-use needles, scalp antisepsis, and halting sessions when pustules or spreading redness appear prevent procedure-related infection.
- Cancer screening up to date: age-appropriate cancer screening before long-term use, and stopping on a new cancer diagnosis, address the theoretical tumor-promotion signal.
- Cosmetic-grade, labeled products only: avoiding unregulated “research peptides” prevents receiving the TB-500 fragment or contaminated material instead of sh-Oligopeptide-4 (Esposito 2012).
- Defined stop rule: stopping when redness or itching persists beyond 72 hours after application, or when shedding rises, limits ongoing irritation.
Therapeutic Protocol
Timing, cycling and titration steps below follow common practice unless cited. No dose-finding study exists for sh-Oligopeptide-4 on the scalp; the doses below are the regimens used in published studies.
- Clinic injection protocol (QR678 Neo): 1.5 mL injected into the scalp every 4 weeks for 8 sessions (Shome 2022); popularized by Kapoor and Shome of The Esthetic Clinics, Mumbai, whose first study injected every 3 weeks (Kapoor 2018).
- Ingredient concentration in injectables: thymosin β4 is stated as 0.005–100 mg/L in the QR678 formulations (Kapoor 2020); the exact sh-Oligopeptide-4 content of QR678 Neo is not disclosed.
- Derma-roller alternative: the same formula applied after derma rolling gave somewhat smaller, non-significant differences versus injection (Shome 2021).
- Topical scalp gel: 0.5 mg/mL recombinant thymosin β4 gel every other day for 4 weeks was the regimen tested for scalp dermatitis (Yu 2021).
- Cosmetic serums and shampoos: concentrations are rarely disclosed; use follows the product label, typically once daily to a dry scalp.
- Competing approach: established medicines (minoxidil, finasteride) have far larger evidence bases; QR678 Neo was also studied with them, but those results appear only in a letter (Shome 2021).
- Time of day: no study compared timing; evening application of leave-on serums allows longer contact before washing or sweating.
- Half-life: intravenous thymosin β4 clears with a half-life of 0.5–2.08 hours (Wang 2021); local scalp persistence after topical use has not been measured.
- Single versus split dosing: single application per day or per session; no study tested split dosing.
- Genetic polymorphisms: no variant is known to influence dose choice.
- Sex: men dominate trials; women received the same 1.5 mL injection regimen in small series (Shome 2022), with no sex-specific dosing.
- Age: the randomized transplant trial enrolled men aged 25–50 (Gold 2025); no age-based dose adjustment exists, though needle sessions may be less tolerable on thin, older scalps.
- Baseline biomarkers: no laboratory value guides dosing; baseline hair density and shaft diameter by trichoscopy (magnified scalp imaging) define the starting point.
- Pre-existing conditions: scalp dermatitis may be treated alongside, as gel improved it (Yu 2021); scarring alopecia is unlikely to respond.
Discontinuation & Cycling
- Short-term or ongoing: injection courses are finite (8 sessions); topical cosmetics are used open-ended, and whether gains persist after stopping is untested beyond one year (Kapoor 2018).
- Withdrawal effects: none reported; the scalp-dermatitis benefit faded partly after stopping the gel (Yu 2021).
- Tapering: not applicable; there is no physiological dependence, so products can be stopped at once.
- Cycling: no evidence that cycling preserves effect; clinic programs repeat courses when shedding returns, which reflects practice, not trial data.
Sourcing and Quality
- Ingredient identity: sh-Oligopeptide-4 is recombinant thymosin β4 made in E. coli (EU CosIng record); it is distinct from Glycyl sh-Oligopeptide-4, rh-Oligopeptide-4, Oligopeptide-4 and the TB-500 fragment.
- Labeling inconsistency: QR678 Neo’s developers describe it as plant-derived (Kapoor 2020), whereas the regulatory record describes bacterial production; buyers cannot verify the source from labels.
- Concentration disclosure: most serums list sh-Oligopeptide-4 near the end of the ingredient list without stating amounts; only brands that publish peptide concentration and stability data allow the dose actually applied to be known.
- Suppliers and brands: the raw ingredient is supplied by Korean peptide maker Caregen as CG-Thymosin β4; QR678 Neo is administered only through licensed clinics.
- Third-party testing: no independent testing program covers peptide cosmetics; mass-spectrometry identity testing, as used in doping control (Esposito 2012), is the only way to confirm content.
- “Research use only” vials: injectable peptides sold online are not made to pharmaceutical standards and may be mislabeled.
Practical Considerations
- Time to effect: the first injection study gave sessions every 3 weeks and assessed results after the 4th and 8th sessions and 2 months later (Kapoor 2018), roughly 2–7 months in; topical cosmetics have no measured time course.
- Common pitfall – mistaking fragments for the full peptide: TB-500 and other “thymosin” products are not sh-Oligopeptide-4, and the hair data do not transfer.
- Common pitfall – replacing proven medicines: using a cosmetic peptide instead of established treatments risks continued follicle loss during unproven use.
- Regulatory status: sh-Oligopeptide-4 is listed in the EU as a skin-conditioning cosmetic ingredient (EU CosIng record); for the US Food and Drug Administration, a product claiming to restore hair growth is a drug (FDA cosmetic-or-drug guidance).
- Cost and access: injectable courses require 8 clinic visits and are available mainly through the developers’ licensed clinic network; insurers do not cover cosmetic hair-loss care, so no payer incentive shapes this evidence.
Interaction with Foundational Habits
- Sleep: no direct interaction; no study links thymosin β4 products to sleep. Indirect: short sleep raises stress-related shedding, which can mask any effect when judging results.
- Nutrition: no direct interaction or nutrient depletion is known. Indirect: protein, iron and zinc shortfalls impair hair growth independently, so correcting them avoids confounding; food timing is irrelevant for topical or scalp-injected use.
- Exercise: no direct interaction. Practical: heavy sweating soon after application may dilute leave-on serums, so applying after training or in the evening preserves contact time; skipping sweat-heavy workouts for 24 hours after needling limits infection risk.
- Stress management: indirect interaction; psychological stress triggers telogen effluvium (stress-induced shedding), which no peptide addresses. Stress reduction supports hair retention, and stress-related shedding can be mistaken for treatment failure.
Monitoring Protocol & Defining Success
Before starting, a baseline assessment establishes the reference point: standardized scalp photographs from the same angles and lighting, a trichoscopy count of hair density and shaft diameter in a marked area, and a hair pull test. A clinician also confirms the type of hair loss, because scarring forms are not expected to respond and other causes of shedding need separate treatment. No baseline laboratory tests are required for topical use.
Ongoing monitoring follows a set cadence: photographs and trichoscopy at 3, 6 and 12 months, the same points at which the injection studies judged results, plus a skin check after each application week in the first month for itching or redness. Success means more terminal hairs or thicker shafts than at baseline, not only less shedding.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Terminal hair count (trichoscopy) | No established target; track change from the individual’s own baseline | Expected to change: primary outcome in QR678 Neo trials | Same scalp site, magnification and lighting each time; trials reported counts per field (Gold 2025); no conventional reference range exists |
| Hair shaft diameter (trichoscopy) | No established target; track change from the individual’s own baseline | Expected to change: thicker shafts signal reversal of miniaturization (shrinking follicles) | Measured alongside counts; changes are small, so readings are comparable only with the same device each visit |
| Hair pull test | No established target; track change from the individual’s own baseline | Expected to change: marker of active shedding | Performed on hair unwashed for 24 hours; gentle traction on about 60 hairs |
| Scalp redness and itching (skin check) | No established target; any persistent reaction is relevant | Safety check: persistent reaction stops use | Reactions seen with thymosin β4 gel (NCT00832091); check within 72 hours of new product |
Qualitative markers:
- Visible scalp coverage in standardized photographs
- Amount of hair shed on the pillow, in the shower and when brushing
- Hair volume and styling ease
- Scalp comfort, flaking and itch
Emerging Research
- No registered hair trial: ClinicalTrials.gov lists no study of sh-Oligopeptide-4, thymosin β4 or QR678 formulations for hair loss; the human hair evidence will remain single-network and combination-only until one is registered.
- Recombinant thymosin β4 in heart attack (NL005): phase 2, 189 participants, primary endpoint infarct size (heart muscle damage) at day 90, not yet recruiting (NCT07586865). A positive or null efficacy result would not change the hair conclusion; clean safety would ease systemic-exposure concerns, new harms would weigh against all forms.
- Thymosin β4 eye drops (SEER-2): phase 3, 70 participants with neurotrophic keratopathy (non-healing corneal surface), completed July 2026, no results posted (NCT05555589). Its safety data concern topical exposure; positive or null efficacy would not change the hair conclusion.
- Independent single-ingredient trial: a systematic review grades QR678 formulations weakly (Joerg 2026); a placebo-controlled trial of sh-Oligopeptide-4 alone, outside the developers’ network, could strengthen or overturn the case.
- Skin penetration studies: whether a peptide of this size crosses intact scalp skin is unmeasured (Bos 2000); a negative finding would weaken the case for leave-on cosmetics.
- Long-term cancer safety: conflicting tumor data (Cha 2003, Caers 2010) need follow-up of long-term users; any signal would outweigh modest cosmetic gains.
Conclusion
sh-Oligopeptide-4 is the cosmetic name for a laboratory-made copy of a natural repair protein, sold in hair serums and in a clinic injection mix. The case for it rests on a coherent animal story: in rodents the protein speeds hair regrowth by moving the stem cells that restart hair growth and by improving blood supply around the root.
Human evidence is thin and indirect. Every hair study in people used a mix of several repair-signal ingredients injected into the scalp, almost all from the group that developed the mix, and none tested this ingredient alone. Those studies point toward more and thicker hairs, but they cannot show what this single ingredient contributes. The clearest human finding for the protein alone concerns a flaky, inflamed scalp rather than regrowth. Whether a protein this large even passes through intact skin from a leave-on serum is unknown.
The safety record of the protein applied to skin or injected into veins is reassuring over weeks, with mild skin itching and redness the main issues, and needle delivery adds pain and redness of its own. A longer-term question remains open because the protein helped tumors spread in mice, while human cancer data point in both directions.
For a proactive adult focused on keeping hair, this ingredient sits at the experimental edge: biologically plausible, commercially promoted, and backed mainly by its developers.